Kemp Doliver

“So, it sounds like you're assuming that patients who are in traditional Medicare will use compounded product because it's dirt cheap. and so any upside related to that is going to be in that population.”

“I'll ask two or three questions and go back in the queue. First of all, when I look at the growth in systems revenue year over year, how comparable is that revenue in the context of the mix of purchases versus leases, since that could impact how the numbers flow through the income statement?”

“I did miss the first few minutes of the presentation, but I think you can go on to add some information What are you doing with regard to collections? It looks like you've made some progress on reducing receivables, but it's hard to tell given the restatements, you know, where you stand currently on that initiative.”

“What do you see as the gating factors behind demand now? You know, if you look back over the history of the launch, you know, there was reimbursement. There was compounded product in a lot of offices and on the market.”